ISPOR 2025 Award Winners

ISPOR recently released their award winners from their 2025 conference this May. Winners are listed below. I’m excited to announce that my podium presentation “Quantifying Treatment Value Using Alternative Health Benefit Metrics: A Case Study of Adjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following Resection” received an award for the Best General Podium…

Inequalities in CAR T-Cell Therapy Access for US Patients with Relapsed/Refractory DLBCL

That is the title of my recent publication with co-authors Andrea Chung, Sachin Vadgama, Kristen Hurley, Miguel-Angel Perales, Leonard Clarkson Alsfeld, Sanjana Muthukrishnan and Anik R Patel, Gunjan L Shah, Richard T Maziarz. The abstract is below. CAR T-cell therapy has shown curative potential for patients with diffuse large B-cell lymphoma (DLBCL) and other malignancies,…

Can Recurrence-Free or Disease-Free Survival be used Surrogate Endpoints for Overall Survival in Esophageal Cancer?

The answer appears to be ‘yes’ according a recent paper written by Uchechukwu Love Anyaduba, Oluwatosin Qawiyy Orababa, Zion Faye, Nazia Rashid, Gregory Reardon and myself. The abstract is below: BackgroundCancer trials increasingly use surrogate endpoints, but it is unclear how well recurrence-free survival (RFS) or disease-free survival (DFS) specifically predict overall survival (OS) in…

Out of Pocket Costs for Follow-Up Tests After Abnormal Screening Mammogram and Their Impact on Breast Cancer Survival

Today, the American Cancer Society’s Cancer Action Network released a report titled “Out of Pocket Costs for Follow-Up Tests After Abnormal Screening Mammogram and Their Impact on Breast Cancer Survival.” The empirical analysis was conducted by myself and some colleagues at FTI Consulting (Shanshan Wang, Shurui Zhang, Citseko Staples Miller, and Sophia Mildred Setterberg). An…

Economic Value of Bronchoscopy Technologies that Improves Sensitivity for Malignancy for Peripheral Pulmonary Lesions

That is the title of my new paper in Annals of the American Thoracic Society with co-authors David Ost, Fabien Maldonado, Jaehong Kim , Moises Marin, Tony Amos, Deanna Hertz, Iftekhar Kalsekar, and Anil Vachani. The abstract is below. Rational: While previous studies have assessed the clinical or economic value of specific technologies, the economic…

What is ‘Bayesian Hierarchical Modelling’ and how can it be used to evaluate oncology treatments studied in basket trials?

Should payers cover a new oncology treatment targeting specific biomarkers across multiple tumor types? One the one hand, one could require a separate trial for each tumor type. While this would be convincing evidence, it also is very expensive to conduct clinical trials for every tumor type, particularly if treatment efficacy is homogenous across tumor…